JMP Securities Reiterates a Buy Rating on Axovant SciencesBy Carrie Williams
According to TipRanks.com, Butler is a 1-star analyst with an average return of -3.6% and a 32.8% success rate. Butler covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Flamel Technologies S.A., and ACADIA Pharmaceuticals.
Currently, the analyst consensus on Axovant Sciences is Moderate Buy and the average price target is $29, representing a 141.3% upside.
In a report released yesterday, Jefferies also reiterated a Buy rating on the stock with a $31 price target.
The company has a one year high of $21.30 and a one year low of $8.86. Currently, Axovant Sciences has an average volume of 455.6K.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AXON in relation to earlier this year.
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. It offers RVT-101 product which is an orally administered therapy that improves cognition and daily functioning of dementia patients. Axovant Sciences was founded on October 31, 2014 and is headquartered in Hamilton, Bermuda.